Back to Search
Start Over
Fabry disease and COVID-19: international expert recommendations for management based on real-world experience
- Source :
- Molecular Genetics and Metabolism, Clinical Kidney Journal, Biblos-e Archivo. Repositorio Institucional de la UAM, instname
- Publication Year :
- 2020
-
Abstract
- The rapid spread of coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 has raised questions about Fabry disease (FD) as an independent risk factor for severe COVID-19 symptoms. Available real-world data on 22 patients from an international group of healthcare providers reveals that most patients with FD experience mild-to-moderate COVID-19 symptoms with an additional complication of Fabry pain crises and transient worsening of kidney function in some cases; however, two patients over the age of 55 years with renal or cardiac disease experienced critical COVID-19 complications. These outcomes support the theory that pre-existent tissue injury and inflammation may predispose patients with more advanced FD to a more severe course of COVID-19, while less advanced FD patients do not appear to be more susceptible than the general population. Given these observed risk factors, it is best to reinforce all recommended safety precautions for individuals with advanced FD. Diagnosis of FD should not preclude providing full therapeutic and organ support as needed for patients with FD and severe or critical COVID-19, although a FD-specific safety profile review should always be conducted prior to initiating COVID-19-specific therapies. Continued specific FD therapy with enzyme replacement therapy, chaperone therapy, dialysis, renin–angiotensin blockers or participation to clinical trials during the pandemic is recommended as FD progression will only increase susceptibility to infection. In order to compile outcome data and inform best practices, an international registry for patients affected by Fabry and infected by COVID-19 should be established.
- Subjects :
- medicine.medical_specialty
Medicina
medicine.medical_treatment
Endocrinology, Diabetes and Metabolism
Population
Renal function
Pathogenesis
Disease
030204 cardiovascular system & hematology
Biochemistry
Article
03 medical and health sciences
0302 clinical medicine
Endocrinology
Pandemic
medicine
Genetics
030212 general & internal medicine
Risk factor
AcademicSubjects/MED00340
Intensive care medicine
education
Molecular Biology
Dialysis
Fabry disease
Transplantation
education.field_of_study
SARS-CoV-2
business.industry
Prevention
Special Feature
COVID-19
Chloroquine
Enzyme replacement therapy
medicine.disease
Lysosome
Clinical trial
Nephrology
Complication
business
Subjects
Details
- ISSN :
- 20488505
- Volume :
- 13
- Issue :
- 6
- Database :
- OpenAIRE
- Journal :
- Clinical kidney journal
- Accession number :
- edsair.doi.dedup.....175338a45efdf26392aac6d7ec9645c0